INNOVATIVE BIORESEARCH

Innovative Bioresearch is an Italian biotechnology company whose principle objectives are the introduction of innovations in the battle/fight against HIV, cancer and human regeneration. The company was founded by the Italian researcher Jonathan Fior in 2014. Innovative Bioresearch ICO was established to raise funds for the support of medical research by Innovative Bioresearch, and to develop an application that would guarantee that all future clinical data collected by the modern decentralized base were created, and at the same time create a social platform for the seropositive HIV community and other additional services.

The main problem today is a number of inconveniences in the currently existing centralized databases for clinical information. All the data obtained in the course of medical scientific research are combined into one scientific article, which is then published in a scientific journal that previously passed a series of independent examinations (also published in the public NIH database). After a new therapeutic strategy goes through all stages of clinical research, many groups of researchers can begin to conduct experiments. After the final approval of the therapy, the treatment can be prescribed directly for the patients. All this means that when the research team wishes to conduct a specific clinical study, In fact, all patients have individual characteristics, so a personalized treatment protocol is required.

Similar problem that arises in the administration of approved treatment to patients, since it is necessary to go through a huge list of documentation to determine the correct treatment protocol. This isn't only a tedious process, it can also lead to a factor of human error. Innovative Bioresearch proposes to solve such problems with access to clinical data by creating a new decentralized database based on block-technology. This will be done in a new application called "You're not alone". The application will be equipped with a convenient interface that allows clinicians to enter a wide range of individual parameters of each patient (age, height, stage of the disease, ethnicity, etc.), the results of treatment and clinical protocols.

ICO Tokens
• Platform: Ethereum
• Type: ERC20
• Pre ICO Price: 1 ETH = 498 INNBC
• Price ICO: 1 ETH = 415INNBC
• Soft Cap Pre-ICO: 20 million INNBC
• Soft Cap ICO: 30 million INNBC
• Hard Cap: 50 million INNBC
• Pre ICO: May 1, 2018-15 June 2018. 20% bonus
• ICO: June 16, 2018-1 August 2018

Distribution Of Funds:
• 50% of all funds will go to further research on AIDS treatment methods;
• 20% will allocate for the development of the ecosystem;
• 15% will go to develop the application;
• 10% for automobile JDM stock;
• 5% of the remaining funds will go to maintain and maintain the application.

Access to the use of INNBC-tokens will be opened only after all the crypto currency has been sold out during the ICO. Also, the holders of the Innovative Bioresearch currency will be able to sell it to other users, thereby giving the latter access to the platform.

Innovative Bioresearch wants to give all its investors something more, supporting the value of INNBC-tokens also physically. To this end, directly after the finish of the ICO, the company will open INNBC JDM ONLINE GARAGE, where investors can purchase JDM cars for their tokens.

Roadmap
2018:
• May - preliminary stage of the ICO;
• June - the main stage of the sale of tokens;
• August - launch of the platform;
• October - the beginning of research in the field of HIV / AIDS;
• December - the beginning of clinical trials.

2020 :
• The beginning of four stages of clinical trials lasting 5-8 years.
• It is planned to obtain commercially available medicines by 2025-2028. The launch of the application for the use of the clinical trials database is expected within 3-6 months after the end of the ICO.

Team
The basis of Innovative Bioresearch consists of three people, thus forming a strong and cohesive team:
• Jonathan Fior (owner, chief scientist, scientist and businessman)
• Davide Bosetti (manager of social networks)
• Alessandro Gatti (chief legal consultant).
Despite the fact that the composition of the project is small in number, Innovative Bioresearch employs many companies and research centers with more than 100 employees.

Conclusion
The non-standard approach to project financing is combined with a well-thought-out concept of its development. Its authors intend to challenge one of the most important problems of modern humanity - HIV / AIDS and cancer.

In addition to the ICO to raise funds for the development of the project, the team has planned a car sales service for platform tokens and placement of profile advertising to ensure a stable and constant inflow of funds for research. The platform will offer not only the sale of vehicles of such brands as Subaru, Skyline and Supra, but will also ensure their delivery to customers anywhere in the world.

The potential success of the project is also evidenced by the experience of his leader, who is already the author of promising research and scientific work in the field of finding ways to treat HIV and cancer.

For More Information:
Website:
WhitePaper:
Bitcointalk Thread:
ANN:
Twitter:
Facebook:
Youtube:

Author : Maniecool
Bitcointalk profile link: https://bitcointalk.org/index.php?action=profile;u=1692995
ETH Address: 0xc7a5bdAa10D8C40f7a7FAF35995C794bB769166b